← vista completa

Publicado el 1 de febrero de 2009 | http://doi.org/10.5867/medwave.2009.02.3772

Efectos del Orlistat más allá de la reducción de peso

Orlistat effects beyond weight reduction

Stephan Jacob

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Stephan Jacob

Universidad de Tubinga, Tübingen, Alemania

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Jacob S. Orlistat effects beyond weight reduction. Medwave 2009;9(02):e3772 doi: 10.5867/medwave.2009.02.3772

Envío 01/01/1970

Aceptación 01/01/1970

Publicación 01/02/2009

Métricas

Vistas en HTML

150

Descargas en PDF

15

Total

165

% Descargas en PDF

10%

Ver detalle

Notas

Referencias

  1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998 Sep;21(9):1414-31. | CrossRef | PubMed
  2. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, et al. Body weight and mortality among women. N Engl J Med. 1995 Sep 14;333(11):677-85. | CrossRef | PubMed
  3. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol. 1992 Sep 15;70(7):733-7. | CrossRef | PubMed
  4. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001 Apr;24(4):683-9. | CrossRef | PubMed
  5. The prevalence of the metabolic syndrome (MS) in non-diabetic German Caucasians: The Sankt Georgen Study (SGS). Meeting Abstract. | Link
  6. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11-17;364(9438):937-52. | CrossRef | PubMed
  7. Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol. 2006 May 16;47(10):1919-26. Epub 2006 Apr 24. | CrossRef | PubMed
  8. Vasudevan AR, Ballantyne CM. Cardiometabolic risk assessment: an approach to the prevention of cardiovascular disease and diabetes mellitus. Clin Cornerstone. 2005;7(2-3):7-16. | CrossRef | PubMed
  9. Després JP. Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease. J Endocrinol Invest. 2006;29(3 Suppl):77-82. | PubMed
  10. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, et al. Absence of an effect of luposuction on insulin action and risk factors of coronary disease. N Engl J Med. 2004 Jun 17;350(25):2549-57. | CrossRef | PubMed
  11. Foster GD, Wadden TA, Vogt RA, Brewer G. What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol. 1997 Feb;65(1):79-85. | CrossRef | PubMed
  12. Malone M. Medications associated with weight gain. Ann Pharmacother. 2005 Dec;39(12):2046-55. Epub 2005 Nov 8. | PubMed
  13. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998 Jul 18;352(9123):167-72. | CrossRef | PubMed
  14. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998 Aug;21(8):1288-94. | CrossRef | PubMed
  15. Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009 Apr;11(4):361-71. Epub 2009 Jan 22. | CrossRef | PubMed
  16. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006 Dec;29(12):2632-7. | CrossRef | PubMed
  17. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care. 2004 Jan;27(1):33-40. | CrossRef | PubMed
  18. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403. http://dx.doi.org/10.1056/NEJMoa012512 | PubMed
  19. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004 Jan;27(1):155-61. | CrossRef | PubMed